Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Single-blind Comparative Clinical Study of Efficacy and Safety of Amizon 0.25 g Tablets, Manufactured by Farmak JSC, in Patients With ARVI, Including Influenza.

NCT04682444 is registered in ClinicalTrials.gov with Joint Stock Company "Farmak" as lead sponsor.

NCT NCT04682444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Single-blind Comparative Clinical Study of Efficacy and Safety of Amizon 0.25 g Tablets, Manufactured by Farmak JSC, in Patients With ARVI, Including Influenza.
Lead sponsor
Joint Stock Company "Farmak"
Phase
Phase 2/3
Overall status
Completed
Start date
April 13, 2009
Completion date
January 15, 2010
Enrollment
100 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory viral infections, human influenza